IgG Responses to Tissue-Associated Antigens as Biomarkers of Immunological Treatment Efficacy by Smith, Heath A. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 454861, 10 pages
doi:10.1155/2011/454861
Research Article
IgG Responsesto Tissue-Associated Antigens as
Biomarkersof ImmunologicalTreatment Efﬁcacy
HeathA.Smith,1 BrettB.Maricque,1 JohnEberhardt,2 BenjaminPetersen,2 James L. Gulley,3
Jeffrey Schlom,3 andDouglasG.McNeel1,4
1Carbone Comprehensive Cancer Center, University of Wisconsin, 1111 Highland Avenue, Madison, WI 53705, USA
2DecisionQ Corporation, 1010 Wisconsin Avenue NW, Suite 310, Washington, DC 20007, USA
3Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892, USA
47007 Wisconsin Institutes for Medical Research, 1111 Highland Avenue, Madison, WI 53705, USA
Correspondence should be addressed to Douglas G. McNeel, dm3@medicine.wisc.edu
Received 1 September 2010; Accepted 12 November 2010
Academic Editor: Timothy M. Clay
Copyright © 2011 Heath A. Smith et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We previously demonstrated that IgG responses to a panel of 126 prostate tissue-associated antigens are common in patients
with prostate cancer. In the current report we questioned whether changes in IgG responses to this panel might be used as a
measure of immune response, and potentially antigen spread, following prostate cancer-directed immune-active therapies. Sera
were obtained from prostate cancer patients prior to and three months following treatment with androgen deprivation therapy
(n = 34),apoxviralvaccine(n = 31),andaDNAvaccine(n = 21).ChangesinIgGresponsestoindividualantigenswereidentiﬁed
by phage immunoblot. Patterns of IgG recognition following three months of treatment were evaluated using a machine-learned
Bayesian Belief Network (ML-BBN). We found that diﬀerent antigens were recognized following androgen deprivation compared
with vaccine therapies. While the number of clinical responders was low in the vaccine-treated populations, we demonstrate that
ML-BBN can be used to develop potentially predictive models.
1.Introduction
Over the last two decades many new immunotherapy
approaches to the treatment of cancer have entered clinical
development due to the increased understanding of the
mechanisms of antigen presentation, lymphocyte recogni-
tion, functions of the innate immune system, and the means
of regulation of these responses and the means by which
tumors can circumvent these responses. Many of these inves-
tigations have led to agents approved for standard clinical
use, including infusional cytokine therapies for melanoma
or renal cell cancer, intravesical BCG therapy for bladder
cancer, and most recently an active cellular therapy targeting
prostatic acid phosphatase (PAP, sipuleucel-T, Provenge,
Dendreon) for patients with advanced metastatic prostate
cancer.Manyotheragentshavedemonstratedbeneﬁtinlarge
clinical trials, and approval is anticipated in the case of a
monoclonal antibody targeting a T-cell checkpoint inhibitor
targeting CTLA-4 (ipilimumab, Bristol-Myers Squibb) for
advanced melanoma.
Ultimately, for these agents to be clinically approved
there needs to be a demonstration that these treatments are
relatively safe and patient care and outcome are positively
aﬀected.However,thereisalsoanincreasingrecognitionthat
some of these agents, while likely safe, may best be used in
combination with other immune-activating or conventional
therapies. This has presented challenges for evaluating these
agents using traditional paradigms for clinical development.
Consequently there is a need to identify markers of biolog-
ical response, ideally associated with clinical outcome, but
permitting an evaluation of biological eﬀect of these agents
used in combination. In the case of antigen-speciﬁc vaccines,2 Journal of Biomedicine and Biotechnology
it has been relatively straightforward to evaluate immune
responses to the target antigen as a “biomarker” of immuno-
logical eﬃcacy. Unfortunately, there are few instances in
which target antigen immune response has been associated
with clinical beneﬁt. The situation is more diﬃcult for
broadly active immune modulating agents such as T-cell
checkpoint inhibitors, including antibodies targeting CTLA-
4 or PD-1, or TLR agonists, in which appropriate biomarkers
of response have been more elusive. Studies with anti-
CTLA-4monoclonalantibodies,inparticular,havesoughtto
identify whether ampliﬁcation of other T-cell costimulatory
molecules [1], or antibodies to deﬁned antigenic tumor-
associated proteins [2, 3], might be useful as biomarkers.
For whole cell tumor vaccines where there is not a speciﬁc,
deﬁned antigen being targeted, surrogate antigens known to
be expressed by the tumor vaccine have been used as a means
of monitoring immune responses from the vaccine [4].
The use of immunologically recognized surrogate antigens,
including HER-2/neu, MUC1, and p53, has been possible in
the case of breast cancer where T-cell and IgG responses to
these antigens have been identiﬁed. However it is unknown
whether responses to these antigens can be useful to study
agents in combination or whether changes in responses to
these antigens are associated with clinical outcome.
Over the last several years we have used SEREX- (sero-
logical analysis of recombinant cDNA expression libraries)
based studies to identify immunologically recognized pro-
teins expressed by normal and malignant prostate tissue
that might serve as targets for anti-tumor vaccines [7]. In
particular, we have evaluated the targets of IgG responses in
patients with chronic prostatitis or autoimmune disorders
[8, 9], patients with prostate cancer treated with immune-
modulating therapies [10], and IgG responses to cancer-
testis antigens in patients with prostate cancer [11, 12]. Over
the course of these studies we have eﬀectively identiﬁed
hundreds of immunologically recognized proteins associated
with prostate tissue and/or recognized by patients with
prostate cancer. While the identiﬁcation of hundreds of
proteinspresentschallengesinprioritizationforthedevelop-
ment of antigen-speciﬁc vaccines, we previously questioned
whether these antigens might also have diagnostic value
with IgG responses being able to distinguish individuals
with prostate cancer (or other inﬂammatory conditions of
the prostate) from men without prostate disease. Other
groups have similarly reported that IgG responses to tissue-
associated antigens might have diagnostic value in identify-
ing patients with prostate cancer [13] or nonsmall cell lung
cancer [14]. We have previously reported that a subset of 23
of these antigens were recognized in patients with prostate
cancer as well as individuals with symptomatic prostatitis,
suggestingthatsuchautoantibodysignaturesmightbeuseful
to identify inﬂammatory conditions of the prostate, and
potentially in a premalignant setting [15].
In the current report, we hypothesized that this same
panel of previously identiﬁed prostate-associated antigens
might be used as a monitoring tool to assess immune
responses elicited following immune-modulating therapy.
While B-cells or IgG production might not be an intended
target of a particular therapeutic approach, IgG responses
are often elicited with concurrent T-cell activation. We
reasoned that IgG responses are easier to measure compared
with antigen-speciﬁc T cells, and might be more stable
over time in the peripheral blood compared with T-cell
frequencies. Moreover, the identiﬁcation of “oﬀ-target” IgG
immune responses might further serve as an indication of
“antigen spread” with secondary antigens recognized fol-
lowing immunological targeting and thus be more relevant
to developing biomarkers associated with favorable clinical
responses.Todetectantibodyresponsestopreviouslydeﬁned
antigens, we applied a similar phage immunoblot approach
evaluatingIgGresponsestomultipleantigenssimultaneously
[15]. These types of complex biomarker data sets are
historically very diﬃcult to work with for two reasons:
ﬁrst is the complexity associated with biological networks;
second is the challenge of infrequent observation of immune
biomarkers in a complex system. As such, the identiﬁcation
of useful biomarkers in data sets such as this study can be
very challenging. In this paper, we sought to evaluate the use
of machine-learned Bayesian Belief Networks (ML-BBNs) as
a method for identifying potentially promising biomarkers
and potential biomarkers networks [16, 17]. We sought to
trainseveralML-BBNstoidentifypromisingbiomarkersand
then use these networks to select a subset of features to
train a network of immune biomarkers as they related to
observed declines in serum prostate-speciﬁc antigen (PSA).
Our objective was to demonstrate the feasibility of this
method to identify promising early biomarkers of immune
response to vaccine therapies in our data.
For the current studies, sera samples were collected
prior to treatment and after three months of treatment
from three separate trials, one in which patients (n =
34) were treated with androgen deprivation (ADT) therapy
only, a standard therapy known to elicit prostate-associated
immune responses [18–20], a trial in which patients with
castrate-resistant prostate cancer (n = 31) were treated
with a viral vaccine encoding PSA (PSAV) [5], and one in
which patients with early recurrent prostate cancer (n = 21)
were treated with a plasmid DNA vaccine encoding PAP
(PAPV) [6]. Patients treated with vaccines were subclassiﬁed
as immunologic or clinical “responders” based on previously
reported criteria to distinguish these groups. We report here
that IgG immune responses could be detected to individual
antigens, and as long as one year after therapy the recog-
nition of speciﬁc antigens was associated with individual
treatments. The evaluation of IgG responses to groups of
antigens at three months suggests that predictive models
mightbedeveloped withdiagnostic potential. Theseﬁndings
support the concept of using measures of “antigen spread”
as biomarkers of immunological eﬃcacy for immune-active
therapies, and IgG responses to panels of tissue-associated
antigens as measures of this antigen spread.
2.MaterialsandMethods
2.1. Patient Populations. Sera used for the studies had been
previously collected with IRB-approved, written consent as
part of three separate clinical trials (Figure 1). All samplesJournal of Biomedicine and Biotechnology 3
Androgen deprivation with 3-month LHRH agonist depot injection
(nonmetastatic, or newly metastatic prostate cancer
without prior androgen-deprivation therapy; n = 34)
Poxviral vaccine (PSA-TRICOM) with Vaccinia-PSA priming immunization
and 2 Fowlpox-PSA booster immunizations at 4-week intervals
(castrate-resistant, metastatic prostate cancer; n = 31)
DNA vaccine encoding PAP, administered 6 times at 2-week intervals
(noncastrate, non-metastatic, PSA-recurrent
prostate cancer; n = 21)
(Timing of blood draws)
∗
∗
Baseline
3-month
Figure 1: Schema for sample collection. Sera were collected from men with prostate cancer undergoing treatment on three separate clinical
trials. Shown are the timing of blood collection and basic schema for these studies. In one study, blood was collected immediately preceding,
and at three months following, standard androgen deprivation therapy with a 3-month depot injection of an LHRH agonist. Patients were
men (n = 34) with prostate cancer who had not previously received androgen depriving therapy, and had PSA-recurrent and/or metastatic
prostate cancer. In the second study, blood was collected immediately preceding and three months following initiation of treatment with a
poxviral vaccine encoding PSA (PSA-TRICOM) [5]. Patients were men (n = 31) with castrate-resistant metastatic prostate cancer. In the
third study, blood was collected immediately preceding, and at three months following, biweekly treatment with a DNA vaccine encoding
prostatic acid phosphatase (PAP) [6]. Patients were men (n = 21) with non-castrate, PSA-recurrent prostate cancer without evidence of
metastatic disease.
were stored at −80◦C until used for analysis. These samples
were all obtained prior to study treatment and after 3
months of treatment in the following settings: (1) a trial
(ADT) in which patients (n = 34) with PSA-recurrent, or
newly metastatic prostate cancer, who had never previously
received androgen deprivation, received 22.5mg leuprolide
by intramuscular injection with or without daily oral
bicalutamide; (2) a trial (PSAV) in which patients (n = 31)
with castrate-resistant, metastatic prostate cancer were vac-
cinated at 2-week intervals with a poxviral vaccine (Prostvac,
vacciniavirusencodingPSAprimingimmunizationfollowed
by fowlpox virus encoding PSA booster immunizations
[5]; (3) a trial (PAPV) in which patients (n = 21) with
PSA-recurrent nonmetastatic prostate cancer, not receiving
androgen deprivation, were vaccinated at 2-week intervals
with a plasmid DNA vaccine encoding PAP [6]. From the
majority of patients treated with ADT (n = 24 of 34) or
PAPV (n = 19 of 21), serum samples were also available 12
months after the baseline sample. From the vaccine studies,
patients were grouped as clinical “responders” or “non-
responders” as simply deﬁned by a decrease in serum PSA
level at the 3-month time point relative to the baseline value.
2.2. High Throughput Immunoblot (HTI). Phage immuno-
blot was performed as we have previously described [15].
In brief, 100,000pfu lambda phage encoding 126 unique
antigens were spotted manually in triplicate in a 16×24 array
onto XL-1 blue E. coli. bacterial lawns in OmniTray plates
using a Biomek FX liquid handling robot. These individual
antigens included 29 cancer-testis antigens [21], 40 proteins
identiﬁedinpatientswithchronicprostatitis[8],and57anti-
gens identiﬁed in individual patients, some of whom were
treated with androgen deprivation or other immunomod-
ulatory therapies [9, 10, 20]. A listing of antigens and
their GenBank Accession numbers is included in Supple-
mental Table 1 in supplementary material available online
at doi:10.1155/2011/454861. Plates were allowed to air-dry
after which 10-mM isopropyl ß-D-thiogalactopyranoside-
(IPTG) suﬀused nitrocellulose membranes were overlain,
and plates incubated at 37◦C overnight to allow recombinant
protein expression. Membranes were then washed, blocked,
and probed with sera from patients pre- or post-treatment,
diluted 1:100 in isotonic buﬀer. Human IgG was then
detectedwithanIgG-speciﬁcsecondaryantibodyconjugated
to alkaline phosphatase and immunoreactivity detected by
developmentwith0.3mg/mLnitrobluetertazoliumchloride
(NBT) (Fisher Biotech) and 0.15mg/mL 5-bromo 4-chloro
3-indoylphosphate (BCIP) (Fisher Biotech). Membranes
were scanned and the digital format was assessed visually,
with individual plaques scored positive or not by four
independent observers, blinded to the treatment, timing
of sample acquisition and membrane layout, as previously
reported [8, 15]. All of the membranes for the entire study
were evaluated by the same observers at the same time.
Triplicate samples were evaluated for each antigen, and
immunoreactivity to individual antigens was scored positive
if there was concordance among 3 of 4 observers, and if
immunoreactivity was scored positive in at least two of4 Journal of Biomedicine and Biotechnology
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Figure 2: IgG responses to prostate-associated antigens are elicited following prostate cancer-directed therapies. Sera from patients
pretreatment and three months following treatment with androgen deprivation ((a), n = 34), a PSA-targeted viral vaccine ((b), n = 31),
or a PAP-targeted DNA vaccine ((c), n = 21) were evaluated for IgG responses to 126 prostate-associated antigens. Antigens (detailed
in Supplemental table 1) are grouped according to the original studies from which they were derived (prostatitis antigens, cancer-testis
antigens, or antigens detected by SEREX from individual subjects), and IgG responses were scored as previously described [15]. Shown is
a heatmap representing gain of response pretreatment to posttreatment (light green), loss of response following treatment (black), or no
change in response (dark green) for all subjects (in rows) and all antigens (in columns).Journal of Biomedicine and Biotechnology 5
the three replicates. Heatmap Builder software (Version 1.1,
Stanford University) was used to generate heatmaps display-
ing changes (gain, loss, or no change) of antibody immune
responses following treatment.
2.3. Statistical Analysis. Our statistical analysis consisted of
using a commercially available machine-learning software
package (FasterAnalytics, DecisionQ Corporation, Washing-
ton, DC). Machine learning is a ﬁeld of computer science
that uses intelligent algorithms to allow a computer to mimic
the process of human learning. Machine learning algorithms
allow the computer to learn dynamically from the data
that resides in the training dataset, detecting associations
between features without human supervision. The machine
learning heuristics generate hypothetical models with dif-
ferent conditional independence assumptions. DecisionQ
software generates several networks simultaneously and then
continues to generate new hypotheses for each network.
The software promotes the network with the best score as
determined by goodness of ﬁt relative to compactness. This
allowsfordenovoexplorationofassociationsincomplexdata
sets.
In preprocessing our data, we compared the pre- and
post-treatment status of biomarkers and encoded the change
in each biomarker as a feature. We then used these encoded
features and clinical response (PSA decline) to train models.
The output of our machine-learning algorithms is a Bayesian
Belief Network (BBN). A BBN encodes the joint probability
distribution of all the variables in the domain by building
a hierarchical network of conditional dependence. The
graphical nature of the network allows the user to query
the structure of conditional dependence to identify those
features which provide the most information content in the
network.Inordertoselectasubsetoffeaturesforinclusionin
a ﬁnal model, we used a stepwise process and trained a series
ofmachine-learned(ML)BBNsforfeatureselection.Weused
this stepwise process as a means of identifying nodes with
relatively high information content given our statistically
challenging biomarker data sets. Because these data sets have
a very high degree of dimensionality (features) relative to
evidence (number of subjects), ﬁnding those features with
the highest information content can be very challenging.
To address this challenge, we trained multiple BBN-ML
models and identiﬁed those features which recurred across
multiplemodelsasevidenceofhighinformationcontent.We
modeled each of our study cohorts (ADT, PSAV, PAPV) and
then compared to the model structures between individual
cohorts to identify shared nodes. We also identiﬁed high-
content nodes (greater than 10 associations) and combined
these with the shared nodes to create a selected subset or
training a ﬁnal model to evaluate a network of biomarkers
to evaluate clinical response (PSA decline). We used our
selected markers to then train three additional models: (i) a
ﬁnal subset model including clinical response (PSA decline)
on the vaccine cohorts, (ii) a model of subjects in the
vaccine studies who were immune responders, and (iii) a
model of subjects who were not immune responders in
the vaccine studies. Finally, we performed tenfold cross-
validation on our clinical response subset model and used
receiver operating characteristic (ROC) curve analysis to
calculate an area-under-the-curve (AUC) metric for the
feature PSA decline, to determine if the subset model could
robustly classify clinical response given immune biomarkers.
The frequencies of IgG responses to individual antigens
were compared between treatment study populations using a
chi-square test.
3. Results
3.1. IgG Responses to Prostate-Associated Antigens are Elicited
Following Prostate Cancer-Directed Immune Therapies. We
have previously reported that antibody responses to prostate
antigens can be detected in patients with prostate cancer
or other inﬂammatory conditions of the prostate [15].
Moreover, a subset of these prostate-associated antigens
was commonly recognized in patients, relative to men
without prostate disease, suggesting that the detection of
IgG responses to speciﬁc prostate-associated antigens might
have diagnostic value. In the current analysis, we wished
to determine whether the detection of IgG responses to
a panel of prostate-associated antigens might have utility
in the evaluation of vaccine or other immunomodulatory
therapies aimed speciﬁcally at eliciting immune responses
to the prostate. For this, we obtained sera from men with
prostate cancer prior to and following three months of
therapy with standard androgen deprivation therapy (n =
34), and from men with prostate cancer (n = 52) prior
to and following three months of therapy with one of two
diﬀerentantigen-speciﬁcvaccines(Figure1).Serafromthese
individuals were used to screen for IgG responses to a panel
of126antigensbyimmunoblot,aspreviouslydescribed[15].
Responsestoallantigenswereevaluatedinblindedfashionat
both time points, and in Figure 2, changes in IgG responses
(gain or loss of response) after 3 months were determined.
As demonstrated, androgen deprivation elicited immune
responses to multiple antigens, and in particular to antigens
previously identiﬁed as antigens recognized in patients with
chronic prostatitis [8, 15]. Responses to these prostatitis
antigens were uncommon over a similar 3-month period in
patients treated with either of the vaccines. Gain or loss of
IgG responses to some antigens appeared to be shared by
these diﬀerent treatments, while responses to some appeared
more speciﬁc for individual treatments. Of note, gain or loss
of IgG responses to PSA, while detected in one individual
treated with ADT, were not detected in patients receiving the
PSA-TRICOM vaccine. Similarly IgG responses to PAP were
not detected in any of the patients, including those receiving
the PAP-targeted vaccine, as previously reported [6].
3.2. IgG Responses to Individual Antigens are Speciﬁc for the
Type of Prostate-Directed Therapy. We next wanted to deter-
mine whether IgG responses observed were generally stable,
or increased over time, and also identify more speciﬁcally
whether responses to some antigens were more generally
associatedwithdiﬀerenttherapies.Inthemajorityofpatients
treated with ADT and PAPV, sera samples were also available
12 months later. Evaluation of IgG responses gained or lost6 Journal of Biomedicine and Biotechnology
Table 1: Biomarker co-occurrence among models. Feature comparison analysis describing which biomarkers have in population speciﬁc
ML-BBNs. An IgG response change to Chromosome 1 gene contig CHANGE1, for example, has associations in all three population-speciﬁc
ML-BBNs. Conversely, an IgG response change to Adducin 1 CHANGE only has an association in the ADT population ML-BBN.
ADT PAPV PSAV Total
Chromosome 1 gene contig CHANGE1 Yes Yes Yes 3
Prolactin-induced protein CHANGE Yes Yes Yes 3
Acetyl-coenzyme A acyltransferase 1 CHANGE No Yes Yes 2
BAC RP11-321G3 CHANGE Yes No Yes 2
Cutaneous T cell CHANGE Yes No Yes 2
neuronal PAS domain protein 2 CHANGE No Yes Yes 2
o-fucosyltansferase CHANGE Yes No Yes 2
Page 1 CHANGE Yes No Yes 2
Recombination signal CHANGE Yes No Yes 2
Adducin 1 CHANGE Yes No No 1
caldesmon 1 (CALD1) CHANGE No Yes No 1
carcimona-associated antigen 64 CHANGE Yes No No 1
Chromosome 1 gene contig CHANGE Yes No No 1
Chromosome 16 gene contig CHANGE Yes No No 1
chromosome 17 CHANGE Yes No No 1
Chromosome 20 gene CHANGE No Yes No 1
Chromosome 4 gene contig CHANGE No Yes No 1
FLJ10710 cDNA CHANGE Yes No No 1
fms-related tyrosine kinase 3 ligand CHANGE No No Yes 1
Helicase with SNF2 domain CHANGE No No Yes 1
Lage 1 CHANGE No Yes No 1
Mage A3 CHANGE Yes No No 1
Ny-ESO1 CHANGE Yes No No 1
PAP associated domain CHANGE Yes No No 1
PAP ELISPOT 12 months No Yes No 1
Plexin B2 CHANGE No Yes No 1
polypeptide E (POLR2E) CHANGE No Yes No 1
Prostate speciﬁc antigen (PSA) CHANGE Yes No No 1
PSA ELISPOT 3m No No Yes 1
Ribosomal protein S27a CHANGE Yes No No 1
RP11-3J10 on chromosome 13 CHANGE No No Yes 1
RP11-738B7 DNA on chromosome 7 CHANGE Yes No No 1
RP11-746L20 DNA on chromosome 8 CHANGE Yes No No 1
SPA17 CHANGE No Yes No 1
after 12 months of ADT, or 12 months after PAP vaccine
treatment compared with baseline demonstrated overall
an increased number of antigens recognized (Figure 3).
Interestingly, responses to individual antigens were observed
to be highly speciﬁc for the treatment. For example, IgG
responses were elicited to the ribosomal L5 protein in 8/24
patients receiving ADT, and 0/19 patients after receiving the
PAPV (P = .005, chi-square test). Similarly, IgG responses
elicited to the neuronal PAS domain protein 2 (NPAS2)
antigen were observed more frequently in patients receiving
the PAP vaccine (5/19) compared with patients receiving
androgen deprivation (0/24, P = .0075, chi-square test).
Even after one year, responses gained or lost to antigens
previously identiﬁed as prostatitis antigens were not detected
in patients treated with the vaccine. While we did not
have access to a control population of sera from untreated
men, given that these represented populations of subjects
with nearly identical stage of disease, collected at the same
institution, the diﬀerences in IgG response patterns to
individual antigens appears most related to the diﬀerence
in treatment. Moreover, these ﬁndings suggest that IgG
responses are elicited to “oﬀ-target” antigens by means of
prostate-directedtherapies,andthepatternsofIgGresponses
diﬀer with respect to therapy.
3.3. Machine-Based Learning Algorithms can be Designed to
Detect Early IgG Response Changes That Might have Predictive
Value. The results above demonstrated that, indeed, IgG
immune responses are elicited as a result of prostate-directed
immune-active therapies. Moreover, antigen-speciﬁc IgGJournal of Biomedicine and Biotechnology 7
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Figure 3: IgG responses to speciﬁc prostate-associated antigens are detectable several months after initiation of treatment with ADT or a
PAP vaccine. Immunoblot analysis was performed with the same panel of antigens using sera from individual subjects for whom sera was
available 12 months after beginning treatment with ADT (24 of the original 34) or the PAP vaccine (19 of the original 21). The heatmap
similarly shows gain of response pretreatment to 12 months posttreatment (light green), loss of response following treatment (black), or no
change in response (dark green) for all subjects (in rows) and all antigens (in columns).
immune responses were highly associated with speciﬁc treat-
ments, suggesting that the generation of immune responses
to these “oﬀ-target” antigens might be associated with other
measures of immune response or clinical outcome. These
responses, however, were most detectable at 12 months
after therapy initiation, a time relatively late to be useful
in most circumstances as a predictive biomarker. Responses
detectable at three months would be more useful. However,
the sample sizes for each individual trial were small, and
multiple comparisons made by evaluating IgG responses to
multiple antigens present diﬃculties in statistically assessing
the importance of an individual marker. Consequently, we
evaluated IgG responses to multiple antigens by training
a ML-BBN model to determine whether we could identify
groups of IgG responses that are associated with clinical
response, using data obtained at three months. Because the
vaccinetrialswereconductedindiﬀerentpatientpopulations
where diﬀerent deﬁnitions of clinical response were used, we
deﬁned it simply for this purpose as a serum PSA value at
the 3-month time point lower than the baseline time point
(n = 1 for the PAPV trial, and n = 4 for the PSAV trial
subjects).
We trained classiﬁers on each cohort and compared
classiﬁer structure between cohorts. We identiﬁed nine (9)
biomarkers that were shared between one or more model
structures, as described in Table 1,a sw e l la st w oh i g h -
contentnodesintheall-cohortmodel.Thisresultedinaﬁnal
subset of biomarkers to include in the ﬁnal ML-BBN model:
chromosome 20 gene contig CHANGE, RP11-738B7 DNA
on chromosome 7 CHANGE, chromosome 1 gene contig
CHANGE1, prolactin-induced protein CHANGE, acetyl-
coenzyme A acyltransferase 1 CHANGE, BAC RP11-321G3
CHANGE, cutaneous T-cell lymphoma tumor antigen sel-
1 CHANGE, neuronal PAS domain protein 2 CHANGE, o-
fucosyltansferase CHANGE, PAGE 1 CHANGE, and recom-
bination signal binding protein (RBPJK) CHANGE. The
structure of the ﬁnal subset model is displayed in Figure 4.
Thisindicatesthattherearetwoﬁrst-degreeassociatesofPSA
decline, IgG responses to chromosome 1 gene contig 1 and
BAC RP11-321G3, and three immune biomarkers features
which can be used to estimate PSA decline: IgG responses to
chromosome 1 gene contig 1, BAC RP11-321G3, and RP11-
738B7 DNA on chromosome 7. Further, these biomarkers
are associated with IgG responses to chromosome 20 gene
contig, o-fucosyltansferase, PAGE 1, and cutaneous T-cell
lymphoma tumor antigen sel-1. To evaluate the robustness
of this model, we performed tenfold cross-validation and
calculated an AUC for clinical response (PSA decline) of
0.357. This indicates that our ﬁrst model is not a robust
classiﬁer, but is rather an exploratory model.8 Journal of Biomedicine and Biotechnology
Acetyl-coenzyme A acyltransferase 1 change
Neuronal PAS domain protein 2 change
BAC RP11-321G3 change Chromosome 20 gene change
PSA decline
RP11-738B7 DNA on chromosome 7 change o-fucosyltansferase change
Chromosome 1 gene contig change1 Cutaneous T cell change Page 1 change
Recombination signal change Prolactin included protein change
Figure 4: Structure of Bayesian Belief Network representing selected subset of biomarkers. The structure of the network represents the
hierarchyofconditionaldependencebetweenfeatures,hencewecanidentifythatthetwoﬁrstdegreeassociatesofclinicalresponsearechange
in IgG responses to BACRP11-321G3 and chromosome 1 gene contig 1. Further, because IgG response to BAC RP11-321G3 is a shared child
between PSA decline and IgG response to RP11-738B7 DNA on chromosome 7, IgG response to RP11-738B7 DNA on chromosome 7 still
inﬂuences the estimate of PSA decline even when IgG response to BAC RP11-321G3 is known.
4. Discussion
In the current report, we sought to determine whether
serum antibody responses to a panel of prostate tissue-
and prostate cancer-associated antigens might be developed
as a diagnostic tool to evaluate immune responses elicited
followingimmune-activetherapies,andfurthertodetermine
whether this might be developed in the future as a biomarker
of clinical response. Using sera obtained from patients
treated with three diﬀerent therapies, we found that antigen-
speciﬁc IgG responses could be detected, likely elicited as
a result of therapy. The patterns of response diﬀered with
respect to the individual therapy, and recognition of speciﬁc
antigens was most evident at a later (12 months following
treatment) than at an earlier time point (3 months following
treatment). Using a ML-BBN model to evaluate groups
of IgG responses detected three months after treatment,
we prioritized a cohort of antigens, immune responses to
which were most associated with PSA decline. These ﬁndings
suggest that, with data from larger populations of subjects,
models could be developed to assist in the detection of
potentially therapeutic immune responses resulting from
immune-based therapies.
Our results demonstrate that immune-active therapies,
including androgen deprivation, elicit IgG responses to
individual prostate-associated antigens. This has already
been demonstrated in previous studies [18, 20]; however,
the IgG responses from androgen deprivation therapy were
mostobviousmanymonthsaftertreatment,whereresponses
to individual antigens were common and predominantly
induced rather than lost. It is conceivable that some immune
responses wax and wane over time, and in fact the detection
of frequent gains and losses of immune responses to indi-
vidual antigens, common across treatment groups detected
earlier at three months, suggests that this can happen with
some antigens. Ideally, to control for this, we would have
preferred to have sera samples from men without prostate
cancerand/ornotundergoingactivetreatmentoverthesame
periods of time. In the absence of this, however, we did have
c o h o r t so fs u b j e c t st r e a t e dw i t hd i ﬀerent therapies. Given
that diﬀerent individual and sets of antigens were speciﬁcally
recognized following these diﬀerent therapies suggests that
the responses observed were not purely by chance or due to
the waxing and waning of responses to individual antigens.
The antigens recognized following androgen deprivation,
in particular, were ones previously demonstrated to be
commonlyrecognizedbyIgGinpatientswithprostatecancer
or inﬂammatory conditions of the prostate [8, 15]. We
did not observe IgG responses to PAP in patients receiving
the PAP-targeted vaccine, nor IgG responses to PSA in
patientsreceivingthePSA-targetedvaccine.Thiswasactually
not unexpected, as we have previously reported that these
vaccines,whileabletoelicitantigen-speciﬁcT-cellresponses,
do not elicit robust antigen-speciﬁc IgG in patients as
detected by more sensitive ELISA methods [6, 22]. The
observation of IgG responses elicited with these treatments
to other antigens suggests that they may be presented by
cross-presentation following immune-mediated tumor cell
targeting.
Of interest was the observation that the antigens recog-
nized following androgen deprivation were diﬀerent from
those recognized following vaccine treatment. Theoretically,
the recognition of other nonvaccine target antigens rep-
resents antigen spread induced by immune targeting and
presentation of other tissue-associated antigens. The recog-
nition of diﬀerent antigens suggests diﬀerent mechanisms
of antigen spread, or potentially recognition of other tissue-
derived antigens, since most of the antigens in this panel are
not prostate speciﬁc in expression. At present it is unclear
whether the generation of such responses is favorable or
not; at least one report has suggested that the generation
of IgG responses to non-target antigens might be associatedJournal of Biomedicine and Biotechnology 9
Table 2: Estimate of PSA decline given biomarker evidence. Inference table describing estimates of the posterior distribution of PSA decline
(target) representing estimates of likelihood of increase (0), decrease (1), or unknown (MISSING). For example, the most common case
involves no change in any of the independent features (biomarkers), occurs 66.7% and results in a 64.1% posterior probability of PSA
increase. The case representing an increase in IgG responses to BAC RP11-321G3, a decrease in IgG response to chromosome 1 gene contig
and no change in IgG response to RP11-738B7 DNA on chromosome 7 occurs 1.1% of the time and results in a 6.9% posterior estimate of
PSA increase.
Probability of
case
Drivers Target
BAC RP11-321G3
CHANGE
Chromosome 1 gene
contig CHANGE1
RP11-738B7 DNA on
chromosome 7 CHANGE
PSA Decline
0.0 1.0 MISSING
0.235% 0.0 −1.0 −1.0 28.6 14.3 57.1
0.168% 1.0 −1.0 −1.0 40.0 20.0 40.0
0.638% 0.0 0.0 −1.0 55.6 6.5 37.9
0.517% 1.0 0.0 −1.0 68.6 8.0 23.4
0.423% 0.0 1.0 −1.0 18.7 6.3 75.0
0.264% 1.0 1.0 −1.0 30.0 10.0 60.0
10.727% 0.0 −1.0 0.0 36.2 13.2 50.6
1.172% 1.0 −1.0 0.0 6.9 48.3 44.8
66.744% 0.0 0.0 0.0 64.1 5.4 30.5
4.311% 1.0 0.0 0.0 20.7 33.6 45.7
11.448% 0.0 1.0 0.0 24.8 6.0 69.2
1.101% 1.0 1.0 0.0 5.4 25.0 69.6
0.235% 0.0 −1.0 1.0 28.6 14.3 57.1
0.168% 1.0 −1.0 1.0 40.0 20.0 40.0
0.638% 0.0 0.0 1.0 55.6 6.5 37.9
0.517% 1.0 0.0 1.0 68.6 8.0 23.4
0.423% 0.0 1.0 1.0 18.7 6.3 75.0
0.264% 1.0 1.0 1.0 30.0 10.0 60.0
with a worse outcome [23]. Future studies will explore
whether the antigens recognized are shared among diﬀerent
vaccine approaches, suggesting common mechanisms of
antigen spread, or whether diﬀerent vaccine therapies elicit
speciﬁc responses to diﬀerent “oﬀ-target” antigens. With
larger group sizes, we also hope to address whether responses
to these antigens are associated with measures of T-cell
immune responses to the target antigen, further implicating
antigen spread as the mechanism of their recognition. In
addition, with larger group sizes we hope to answer whether
these are clearly associated with improved clinical beneﬁt or
not, or whether this is dependent on treatment context and
the speciﬁc antigen(s) recognized, as we expect.
Given the small sample size and the multitude of IgG
response data points, we sought to identify if the use of ML-
BBN modeling was feasible to identify biomarker cohorts in
o u rs t u d yd a t a .W ew e r ea b l et ou s eas t e p w i s ep r o c e s sa n d
BBN model structures to identify those biomarkers which
had high information content for use in a selected subset
for ML-BBN modeling. We were subsequently able to use
this subset to train an ML-BBN including clinical response,
however on cross-validation, our AUC for clinical response
was poor. This is likely due to the fact that of the 52 vaccine
subjects we only had 5 “responders” as deﬁned. This resulted
in a very small set of training outcomes, making models
very sensitive to record deletion, as in the case of cross-
validation. PSA response has itself not been validated as a
surrogate clinical endpoint, and ADT itself elicits initial PSA
responses in the vast majority of patients. Consequently,
future studies will explore other better markers of clinical
response. In addition, as further data are collected from
additional subjects treated by vaccines, we expect this will
produce a more robust predictive model.
In any case, the use of ML-BBN modeling appears to
provide a promising method for identifying biomarkers in
complex data sets that can then be selected for further
analysis, as the same subset of biomarkers appeared to
produce high information content in models across diﬀerent
populations. Further, once we have suﬃcient subjects to pro-
duce a robust model, tables of posterior estimates for clinical
response given combinations of IgG response biomarkers
can be developed. An example inference table is provided in
Table 2,wherethosebiomarkers thatarepredictive ofclinical
response can provide a posterior estimate of response. This
type of inference could support the translation of this
research into a clinical application for determining whether
an individual patient has “responded” from a particular
vaccine therapy or potentially whether ongoing immuniza-
tion should be performed. Future modeling might further
permit the selection of patients who would be appropriate to10 Journal of Biomedicine and Biotechnology
receive vaccine therapy based on pre-existing immunological
response parameters.
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